<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7905840</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6445</journal-id>
<journal-id journal-id-type="nlm-ta">Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Ther.</journal-id>
<journal-title-group>
<journal-title>Pharmacology &amp; therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0163-7258</issn>
<issn pub-type="epub">1879-016X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31051197</article-id>
<article-id pub-id-type="pmc">6859062</article-id>
<article-id pub-id-type="doi">10.1016/j.pharmthera.2019.04.009</article-id>
<article-id pub-id-type="manuscript">NIHMS1034636</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting opioid dysregulation in depression for the development of novel therapeutics</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Browne</surname>
<given-names>Caroline A</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lucki</surname>
<given-names>Irwin</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda MD 20814</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Corresponding author: Dr. Irwin Lucki, Department of Pharmacology &amp; Molecular Therapeutics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, Phone: 301–295–3248, <email>irwin.lucki@usuhs.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P63">Conflict of interest:</p>
<p id="P64">No conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>9</month>
<year>2020</year>
</pub-date>
<volume>201</volume>
<fpage>51</fpage>
<lpage>76</lpage>
<!--elocation-id from pubmed: 10.1016/j.pharmthera.2019.04.009-->
<abstract id="ABS1">
<p id="P1">Since the serendipitous discovery of the first class of modern antidepressants in the 1950’s, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widespread availability of antidepressants, as many as 50% of depressed patients are resistant to these conventional therapies. The significant length of time required to produce meaningful symptom relief with these medications, 4–6 weeks, indicates that other mechanisms are likely involved in the pathophysiology of depression and these mechanisms may yield more viable targets for drug development. For decades, no viable candidate target with a different mechanism of action to that of conventional therapies proved successful in clinical studies. Now several exciting avenues for drug development are under intense investigation. One of these emerging targets is modulation of endogenous opioid tone. This review will evaluate preclinical and clinical evidence pertaining to opioid dysregulation in depression focusing on the role of the endogenous ligands endorphin, enkephalin, dynorphin, and nociceptin/orphanin FQ (N/OFQ) and their respective receptors, mu (MOR), delta (DOR), kappa (KOR), and the N/OFQ receptor (NOP) in mediating behaviors relevant to depression and anxiety. Finally, putative opioid based antidepressants that are being tested in clinical trials, ALKS5461, JNJ–67953964 (formerly LY2456302 and CERC–501) and BTRX–246040 (formerly LY–2940094) will be discussed. This review will illustrate the potential therapeutic value of targeting opioid dysregulation in developing novel therapies for major depression disorder.</p>
</abstract>
<kwd-group>
<kwd>Depression</kwd>
<kwd>MOR –mu opioid receptor</kwd>
<kwd>KOR – kappa opioid receptor</kwd>
<kwd>DOR – delta opioid receptor</kwd>
<kwd>NOP – nociceptin/orphaninFQ receptor</kwd>
<kwd>JNJ–67953964</kwd>
<kwd>Buprenorphine</kwd>
<kwd>ALKS–5461</kwd>
<kwd>BTRX–246040</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>